BioCentury
ARTICLE | Clinical News

Alpharadin: Phase III started

June 23, 2008 7:00 AM UTC

Algeta began the double-blind, international Phase III ALSYMPCA trial in 750 patients to evaluate best supportive care, plus 6 IV doses of kBq/kg Alpharadin at 4-week intervals or placebo. ...